AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12197896 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control)
Number of subjects: 7
Study 9862576 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 75 mg m(‐2) on day 1 (112 patients)
Number of subjects: 334
Study 9862576 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 150 mg m(‐2) on day 1 (111 patients)
Number of subjects: 334
Study 9862576 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 50 mg m(‐2) on days 1, 2, and 3 (111 patients)
Number of subjects: 334
Study 7623523 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) at low doses (30 mg and 100 mg)
Number of subjects: 12
Study 7623523 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) at moderate doses (400 mg)
Number of subjects: 12
Study 7623523 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid (SA) renal clearance
Number of subjects: 12
Study 7623523 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicyluric acid (SUA) renal clearance
Number of subjects: 12
Study 2507152 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix 320
Number of subjects: 0
Study 2507152 — intervention group
Group type: COMPARATOR
Intervention: Hexabrix 250
Number of subjects: 0
Study 67128 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal oxymorphone
Number of subjects: 136
Study 67128 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular oxymorphone
Number of subjects: 136
Study 31822298 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 750
Study 31822298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study 27618386 — intervention group
Group type: EXPERIMENTAL
Intervention: VL15 (15% velocity loss)
Number of subjects: 16
Study 27618386 — intervention group
Group type: COMPARATOR
Intervention: VL30 (30% velocity loss)
Number of subjects: 16
Study 26253566 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial dual therapy (combination therapy)
Number of subjects: 536
Study 26253566 — intervention group
Group type: COMPARATOR
Intervention: Initial monotherapy
Number of subjects: 536
Study 26253566 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 536
Study 24113771 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 12
Study 21857356 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 result at time of HIV diagnosis
Number of subjects: 344
Study 21857356 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information only
Number of subjects: 344
Study 21857356 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (CD4 collection after 1 week)
Number of subjects: 344
Study 17822582 — intervention group
Group type: EXPERIMENTAL
Intervention: CT instruction in civic education (experimental group)
Number of subjects: 68
Study 17822582 — intervention group
Group type: COMPARATOR
Intervention: No CT programme (control group)
Number of subjects: 68
Study 16879829 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.35 g EPA/day
Number of subjects: 100
Study 16879829 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.7 g EPA/day
Number of subjects: 100
Study 16879829 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.05 g EPA/day
Number of subjects: 100
Study 16879829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 16879829 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (all doses)
Number of subjects: 100
Study 16879829 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest dose of EPA
Number of subjects: 100
Study 16879829 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased EPA (all doses)
Number of subjects: 100
Study 15043766 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraorbital keyhole approach using eyebrow incisions
Number of subjects: 54
Study 15043766 — intervention group
Group type: COMPARATOR
Intervention: Conventional subfrontal approach
Number of subjects: 54
Study 11386610 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 10‐mg dose of diazepam
Number of subjects: 0
Study 11386610 — intervention group
Group type: COMPARATOR
Intervention: Drug abusers starting a prison sentence
Number of subjects: 0
Study 9739972 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral famciclovir (125 mg or 250 mg 3 times daily or 250 mg twice daily)
Number of subjects: 455
Study 9739972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study 7979521 — intervention group
Group type: EXPERIMENTAL
Intervention: Height for age z score < -2
Number of subjects: 128
Study 7979521 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight for age z scores
Number of subjects: 128
Study 7979521 — intervention group
Group type: EXPERIMENTAL
Intervention: Age above 8 years
Number of subjects: 128
Study 7979521 — intervention group
Group type: EXPERIMENTAL
Intervention: High peripheral white cell count
Number of subjects: 128
Study 7979521 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 128
Study 2522371 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose containing 10 U l‐1 insulin
Number of subjects: 17
Study 2522371 — intervention group
Group type: COMPARATOR
Intervention: 10% glucose with 40 U l‐1 insulin
Number of subjects: 17
Study 5792911 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg)
Number of subjects: 15
Study 5792911 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% solution, 10 ml)
Number of subjects: 15
Study 30045107 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable leukocyte platelet-rich fibrin (iL-PRF)
Number of subjects: 0
Study 30045107 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study 26693643 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-based liquid meal supplement (Sustagen Sport)
Number of subjects: 7
Study 26693643 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-electrolyte sports drink (Powerade)
Number of subjects: 7
Study 25547902 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/d orally, intermittent administration on days 2 to 16 every 21 days, combined with docetaxel 75 mg/m² every 21 days
Number of subjects: 68
Study 25547902 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib 150 mg/d orally, administered continuously
Number of subjects: 68
Study 22757691 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect moxibustion on CV4 and CV8 3 times per week for 4 weeks
Number of subjects: 44
Study 22757691 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect moxibustion on CV4 and CV8
Number of subjects: 44
Study 20083678 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous atrioventricular antitachycardia pacing
Number of subjects: 63
Study 20083678 — intervention group
Group type: COMPARATOR
Intervention: Convergent atrioventricular antitachycardia pacing
Number of subjects: 63
Study 20083678 — intervention group
Group type: EXPERIMENTAL
Intervention: New pacing algorithm
Number of subjects: 63
Study 18477409 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA-enriched foods
Number of subjects: 44
Study 18477409 — intervention group
Group type: COMPARATOR
Intervention: standard foods (control)
Number of subjects: 44
Study 15727975 — intervention group
Group type: EXPERIMENTAL
Intervention: Persuasive newsletters and a parent-teenager driving agreement
Number of subjects: 469
Study 15727975 — intervention group
Group type: COMPARATOR
Intervention: Standard information on driver safety
Number of subjects: 469
Study 12580986 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide MR (30 mg initial dose)
Number of subjects: 634
Study 12580986 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide MR
Number of subjects: 634
Study 10534989 — intervention group
Group type: EXPERIMENTAL
Intervention: Bracketed enamel sample with pre-formed caries-like lesions
Number of subjects: 15
Study 10534989 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-bracketed enamel sample with pre-formed caries-like lesions
Number of subjects: 15
Study 10534989 — intervention group
Group type: COMPARATOR
Intervention: Control sample (not placed in the mouth)
Number of subjects: 15
Study 8600874 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee brace applied to the tracking limb
Number of subjects: 20
Study 8600874 — intervention group
Group type: COMPARATOR
Intervention: No knee brace
Number of subjects: 20
Study 1914837 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactosaminoglycuronoglycan sulfate (Matrix)
Number of subjects: 40
Study 1914837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7159686 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release quinidine tablet (300 mg)
Number of subjects: 18
Study 7159686 — intervention group
Group type: COMPARATOR
Intervention: Oral quinidine sulfate solution (300 mg)
Number of subjects: 18
Study 31130274 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated care
Number of subjects: 283
Study 31130274 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 283
Study 29726951 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut consumption (42 g walnuts/d)
Number of subjects: 18
Study 25536669 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 3 mg daily
Number of subjects: 31
Study 25536669 — intervention group
Group type: COMPARATOR
Intervention: rosiglitazone (Rosi) 4 mg twice daily
Number of subjects: 31
Study 25536669 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rhGH and Rosi
Number of subjects: 31
Study 25536669 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 31
Study 23582949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Hormonal Therapy (IHT) with cyproterone acetate (CPA) 200 mg/d for 2 weeks, then monthly LHRH analogue plus CPA 200 mg/d.
Number of subjects: 1045
Study 23582949 — intervention group
Group type: COMPARATOR
Intervention: Continuous Maximal Androgen Blockade (MAB) with CPA 200 mg/d plus monthly LHRH analogue.
Number of subjects: 1045
Study 24009704 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness based cognitive therapy (MBCT)
Number of subjects: 130
Study 20204959 — intervention group
Group type: EXPERIMENTAL
Intervention: Long HPV pamphlet
Number of subjects: 499
Study 20204959 — intervention group
Group type: EXPERIMENTAL
Intervention: Short HPV pamphlet
Number of subjects: 499
Study 20204959 — intervention group
Group type: COMPARATOR
Intervention: Long control pamphlet
Number of subjects: 499
Study 20204959 — intervention group
Group type: COMPARATOR
Intervention: Short control pamphlet
Number of subjects: 499
Study 18698881 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-escalation treprostinil dosing regimen
Number of subjects: 23
Study 18698881 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-escalation treprostinil dosing regimen
Number of subjects: 23
Study 18698881 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 23
Study 16538016 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with 2% mepivacaine
Number of subjects: 20
Study 16538016 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia maintained with 2 L of oxygen, 4 L of nitrous oxide, and 1% to 3% isoflurane
Number of subjects: 20
Study 12824786 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF (300 microg by subcutaneous injection three times weekly for 4 weeks)
Number of subjects: 33
Study 12824786 — intervention group
Group type: COMPARATOR
Intervention: STI-only group
Number of subjects: 33
Study 10632688 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (lidocaine 2.5% and prilocaine 2.5%)
Number of subjects: 10
Study 10632688 — intervention group
Group type: EXPERIMENTAL
Intervention: ELA-Max cream (lidocaine 4%)
Number of subjects: 10
Study 10632688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10632688 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (EMLA and ELA-Max combined)
Number of subjects: 10
Study 9121848 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Recording Meter (ERM)
Number of subjects: 65
Study 9121848 — intervention group
Group type: COMPARATOR
Intervention: Simple Mini-Wright (SM)
Number of subjects: 65
Study 9121848 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ERM and SM
Number of subjects: 65
Study 8389667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 2.0 g/m2 days 1 to 3 with cisplatin 33 mg/m2 days 1 to 3
Number of subjects: 25
Study 8389667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 2.5 g/m2 days 1 to 3 with cisplatin 33 mg/m2 days 1 to 3
Number of subjects: 25
Study 8389667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 2.0 g/m2 days 1 to 3
Number of subjects: 25
Study 8389667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 2.5 g/m2 days 1 to 3
Number of subjects: 25
Study 3555033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 20
Study 3555033 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tobramycin plus azlocillin
Number of subjects: 20
Study 30473366 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Together intervention
Number of subjects: 6667
Study 30473366 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (control)
Number of subjects: 6667
Study 26754643 — intervention group
Group type: EXPERIMENTAL
Intervention: Living kidney donors
Number of subjects: 124
Study 23643477 — intervention group
Group type: EXPERIMENTAL
Intervention: Paid advertising (newspaper, radio, television)
Number of subjects: 145
Study 23643477 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpaid advertising (staff visits, flyers, brochures, free media coverage, presentations)
Number of subjects: 145
Study 23643477 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recruitment strategies
Number of subjects: 145
Study 23643477 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall screening and enrollment
Number of subjects: 145
Study 23643477 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention strategies
Number of subjects: 145
Study 25048382 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) 130-139 mmHg
Number of subjects: 1791
Study 25048382 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) >140 mmHg
Number of subjects: 1791
Study 25048382 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP) <40 mmHg
Number of subjects: 1791
Study 25048382 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP) >60 mmHg
Number of subjects: 1791
Study 25048382 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) >140 mmHg with A1C increase
Number of subjects: 1791
Study 22172244 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis (CDT) using alteplase
Number of subjects: 209
Study 22172244 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional treatment)
Number of subjects: 209
Study 20796106 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) covering the Ti-mesh
Number of subjects: 30
Study 20796106 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 30
Study 17561002 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI with COH
Number of subjects: 265
Study 17561002 — intervention group
Group type: COMPARATOR
Intervention: IUI without COH
Number of subjects: 265
Study 15723891 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing focused on traumatic life events
Number of subjects: 47
Study 15723891 — intervention group
Group type: COMPARATOR
Intervention: Writing about a neutral topic
Number of subjects: 47
Study 12081192 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist nurses
Number of subjects: 880
Study 12081192 — intervention group
Group type: COMPARATOR
Intervention: Senior house officers (SHOs)
Number of subjects: 880
Study 11783144 — intervention group
Group type: EXPERIMENTAL
Intervention: Yinhua mixture aerosol
Number of subjects: 102
Study 11783144 — intervention group
Group type: COMPARATOR
Intervention: Gentamycin aerosol
Number of subjects: 102
Study 8874109 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal diet with complete avoidance of milk and eggs during the last trimester of pregnancy and exclusive breast feeding.
Number of subjects: 0
Study 8874109 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal diet with complete avoidance of milk and eggs starting after delivery.
Number of subjects: 0
Study 8874109 — intervention group
Group type: COMPARATOR
Intervention: No dietary restrictions for mothers.
Number of subjects: 0
Study 20054944 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days bed rest
Number of subjects: 51
Study 20054944 — intervention group
Group type: COMPARATOR
Intervention: 7 days bed rest
Number of subjects: 51
Study 6151842 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of temazepam
Number of subjects: 0
Study 6151842 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of flurazepam
Number of subjects: 0
Study 6151842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31658024 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride plus 2-W laser for 15 seconds
Number of subjects: 120
Study 31658024 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride plus 2-W laser for 30 seconds
Number of subjects: 120
Study 31658024 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride plus 2-W laser for 60 seconds
Number of subjects: 120
Study 31658024 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride plus 5-W laser for 15 seconds
Number of subjects: 120
Study 31658024 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride plus 5-W laser for 30 seconds
Number of subjects: 120
Study 31658024 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride plus 5-W laser for 60 seconds
Number of subjects: 120
Study 31658024 — intervention group
Group type: COMPARATOR
Intervention: Fluoride only
Number of subjects: 120
Study 31658024 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 120
Study 31658024 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-W laser groups
Number of subjects: 120
Study 28929925 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-directed occupational therapy intervention
Number of subjects: 0
Study 26861417 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (CHG) bathing
Number of subjects: 33
Study 26861417 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CHG bathing)
Number of subjects: 33
Study 24479576 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Therapy (NT)
Number of subjects: 63
Study 24479576 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 63
Study 22526883 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light pulse (∼10,000 lux) for 0.2 h
Number of subjects: 39
Study 22526883 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light pulse (∼10,000 lux) for 4.0 h
Number of subjects: 39
Study 22526883 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure (varying durations)
Number of subjects: 39
Study 19770162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ashworth Scale (AS) for elbow flexors
Number of subjects: 30
Study 19770162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ashworth Scale (AS) for knee extensors
Number of subjects: 30
Study 17599423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control targeting HbA1c <6%
Number of subjects: 10251
Study 17599423 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic control targeting HbA1c 7.0%-7.9%
Number of subjects: 10251
Study 15961761 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m(2) plus ifosfamide 5 g/m(2) during 24 hours and cisplatin 75 mg/m(2) every 3 weeks for three courses (TIP)
Number of subjects: 219
Study 15961761 — intervention group
Group type: COMPARATOR
Intervention: Ifosfamide 5 g/m(2) during 24 hours plus cisplatin 75 mg/m(2) (IP)
Number of subjects: 219
Study 15961761 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, ifosfamide, and cisplatin (TIP)
Number of subjects: 219
Study 15961761 — intervention group
Group type: COMPARATOR
Intervention: Ifosfamide and cisplatin (IP)
Number of subjects: 219
Study 15961761 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients assessable for response (n = 189)
Number of subjects: 219
Study 11992097 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-83757 (10 mcg, 60-140 mcg)
Number of subjects: 66
Study 11992097 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-83757
Number of subjects: 66
Study 9789364 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 84
Study 9789364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 84
Study 9789364 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 84
Study 9789364 — intervention group
Group type: COMPARATOR
Intervention: Total Intravenous Anaesthesia (TIVA)
Number of subjects: 84
Study 11995905 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) beverage
Number of subjects: 8
Study 11995905 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) beverage
Number of subjects: 8
Study 1297516 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmoscopy examination of optic nerve head and disc pallor measurement from disc photographs
Number of subjects: 120
Study 1297516 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of two methods for detecting early glaucomatous damage
Number of subjects: 120
Study 6835771 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibling visiting
Number of subjects: 16
Study 6835771 — intervention group
Group type: COMPARATOR
Intervention: Nonvisiting group
Number of subjects: 16
Study 30415255 — intervention group
Group type: EXPERIMENTAL
Intervention: mPCNL with ureter catheter
Number of subjects: 60
Study 30415255 — intervention group
Group type: EXPERIMENTAL
Intervention: partial tubeless mPCNL
Number of subjects: 60
Study 30415255 — intervention group
Group type: COMPARATOR
Intervention: mPCNL
Number of subjects: 60
Study 29927289 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive marital discussion
Number of subjects: 115